Flutrends International

Flutrends International is a Hong Kong-based biotechnology company specializing in the development of innovative vaccines for respiratory infectious diseases. The company leverages its proprietary DelNS1 live-attenuated influenza virus vector platform, which was developed at the University of Hong Kong, to create intranasal vaccines that induce potent mucosal immunity. Their lead product, an intranasal COVID-19 vaccine developed in collaboration with Beijing Wantai Biological Pharmacy, has received emergency use authorization in China. Flutrends continues to advance a pipeline of universal and seasonal influenza vaccines, as well as candidates for emerging avian flu strains. The company operates as a key bridge between academic research at the University of Hong Kong and large-scale commercial manufacturing.